ADMA Biologics Inc (NASDAQ:ADMA) shares hit a new 52-week low during trading on Thursday . The company traded as low as $2.87 and last traded at $2.88, with a volume of 23,447 shares trading hands. The stock had previously closed at $3.04.

A number of brokerages have recently commented on ADMA. Maxim Group set a $13.00 price objective on shares of ADMA Biologics and gave the company a “buy” rating in a research report on Wednesday, June 7th. ValuEngine lowered shares of ADMA Biologics from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd.

The company’s 50-day moving average price is $3.47 and its 200 day moving average price is $4.21. The company’s market capitalization is $37.05 million.

ADMA Biologics (NASDAQ:ADMA) last posted its earnings results on Friday, May 12th. The biotechnology company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by $0.23. The firm had revenue of $2.63 million for the quarter, compared to the consensus estimate of $3.35 million. On average, equities research analysts forecast that ADMA Biologics Inc will post ($1.28) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “ADMA Biologics Inc (ADMA) Sets New 12-Month Low at $2.87” was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this news story can be read at

About ADMA Biologics

ADMA Biologics, Inc is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.

Receive News & Ratings for ADMA Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.